432 related articles for article (PubMed ID: 26664108)
1. Switching treatments in COPD: implications for costs and treatment adherence.
Braido F; Lavorini F; Blasi F; Baiardini I; Canonica GW
Int J Chron Obstruct Pulmon Dis; 2015; 10():2601-8. PubMed ID: 26664108
[TBL] [Abstract][Full Text] [Related]
2. The importance of inhaler devices: the choice of inhaler device may lead to suboptimal adherence in COPD patients.
Darbà J; Ramírez G; Sicras A; Francoli P; Torvinen S; Sánchez-de la Rosa R
Int J Chron Obstruct Pulmon Dis; 2015; 10():2335-45. PubMed ID: 26604733
[TBL] [Abstract][Full Text] [Related]
3. Differences in health care outcomes between postdischarge COPD patients treated with inhaled corticosteroid/long-acting β
Wittbrodt ET; Millette LA; Evans KA; Bonafede M; Tkacz J; Ferguson GT
Int J Chron Obstruct Pulmon Dis; 2019; 14():101-114. PubMed ID: 30613140
[TBL] [Abstract][Full Text] [Related]
4. The cost-saving switch from inhaled corticosteroid-containing treatments to dual bronchodilation: a two-country projection of epidemiological and economic burden in chronic obstructive pulmonary disease.
Souliotis K; Silva Miguel L; Hillas G; Borges M; Papageorgiou G; Viana D; Malhadeiro J; Soulard S
Ther Adv Respir Dis; 2020; 14():1753466620926802. PubMed ID: 32519591
[TBL] [Abstract][Full Text] [Related]
5. Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease.
Sicras Mainar A; Huerta A; Navarro Artieda R; Monsó E; Landis SH; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2019; 14():2121-2129. PubMed ID: 31571848
[TBL] [Abstract][Full Text] [Related]
6. [Persistence to treatment by type of inhaler device in patients with asthma and chronic obstructive pulmonary disease].
Sicras A; Ferrer V; Collar JM; Navarro R; Sáez M
Semergen; 2017; 43(5):375-386. PubMed ID: 27425817
[TBL] [Abstract][Full Text] [Related]
7. Trend of cost and utilization of COPD medication in Korea.
Lee J; Lee JH; Kim JA; Rhee CK
Int J Chron Obstruct Pulmon Dis; 2017; 12():27-33. PubMed ID: 28031708
[TBL] [Abstract][Full Text] [Related]
8. Trends in health care resource utilization and pharmacological management of COPD in Taiwan from 2004 to 2010.
Tsai YH; Yang TM; Lin CM; Huang SY; Wen YW
Int J Chron Obstruct Pulmon Dis; 2017; 12():2787-2793. PubMed ID: 29026296
[TBL] [Abstract][Full Text] [Related]
9. Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care.
Punekar YS; Landis SH; Wurst K; Le H
Respir Res; 2015 Nov; 16():141. PubMed ID: 26572740
[TBL] [Abstract][Full Text] [Related]
10. Trends in prescriptions and costs of inhaled medications in chronic obstructive pulmonary disease: a 19-year population-based study from Canada.
Tavakoli H; Johnson KM; FitzGerald JM; Sin DD; Gershon AS; Kendzerska T; Sadatsafavi M
Int J Chron Obstruct Pulmon Dis; 2019; 14():2003-2013. PubMed ID: 31564848
[TBL] [Abstract][Full Text] [Related]
11. Spotlight on glycopyrronium/formoterol fumarate inhalation aerosol in the management of COPD: design, development, and place in therapy.
Dhungana S; Criner GJ
Int J Chron Obstruct Pulmon Dis; 2017; 12():2307-2312. PubMed ID: 28814858
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of early medication use for COPD: a population-based cohort study.
Falk J; Dik N; Bugden S
Int J Chron Obstruct Pulmon Dis; 2016; 11():3101-3108. PubMed ID: 27994449
[TBL] [Abstract][Full Text] [Related]
13. The burden of chronic obstructive pulmonary disease associated with maintenance monotherapy in the UK.
Edwards SC; Fairbrother SE; Scowcroft A; Chiu G; Ternouth A; Lipworth BJ
Int J Chron Obstruct Pulmon Dis; 2016; 11():2851-2858. PubMed ID: 27920512
[TBL] [Abstract][Full Text] [Related]
14. A review of nebulized drug delivery in COPD.
Tashkin DP
Int J Chron Obstruct Pulmon Dis; 2016; 11():2585-2596. PubMed ID: 27799757
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
[TBL] [Abstract][Full Text] [Related]
16. Does Changing Inhaler Device Impact Real-Life Asthma Outcomes? Clinical and Economic Evaluation.
Rhee CK; van Boven JFM; Yau Ming SW; Park HY; Kim DK; Park HS; Ling JZJ; Yoo KH; Price DB
J Allergy Clin Immunol Pract; 2019 Mar; 7(3):934-942. PubMed ID: 30292924
[TBL] [Abstract][Full Text] [Related]
17. Asthma and COPD: Interchangeable use of inhalers. A document of Italian Society of Allergy, Asthma and Clinical Immmunology (SIAAIC) & Italian Society of Respiratory Medicine (SIMeR).
Lavorini F; Braido F; Baiardini I; Blasi F; Canonica GW;
Pulm Pharmacol Ther; 2015 Oct; 34():25-30. PubMed ID: 26209820
[TBL] [Abstract][Full Text] [Related]
18. The reasons for triple therapy in stable COPD patients in Japanese clinical practice.
Miyazaki M; Nakamura H; Takahashi S; Chubachi S; Sasaki M; Haraguchi M; Terai H; Ishii M; Fukunaga K; Tasaka S; Soejima K; Asano K; Betsuyaku T;
Int J Chron Obstruct Pulmon Dis; 2015; 10():1053-9. PubMed ID: 26082629
[TBL] [Abstract][Full Text] [Related]
19. Inhaled drug delivery in the hands of the patient.
Lavorini F
J Aerosol Med Pulm Drug Deliv; 2014 Dec; 27(6):414-8. PubMed ID: 25238005
[TBL] [Abstract][Full Text] [Related]
20. Impact of Single Combination Inhaler versus Multiple Inhalers to Deliver the Same Medications for Patients with Asthma or COPD: A Systematic Literature Review.
Zhang S; King D; Rosen VM; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2020; 15():417-438. PubMed ID: 32161454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
